Abstract
Metal ions, Alzheimer's disease and chelation therapyIn the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference76 articles.
1. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications;D. Skovronsky;Annu. Rev. Pathol. Mech. Dis,2006
2. Epidemiology of neurodegeneration;R. Mayeux;Annu. Rev. Neurosci,2003
3. C. P. Ferri, R. Sousa, E. Albanese, W. S. Ribeiro and M. Honyashiki, World Alzheimer Report 2009 - Executive Summary (Eds. M. Prince and J. Jadeson), Alzheimer's Disease International, London 2009, pp. 1-22; http://www.alz.co.uk/adi/publications.html
4. Alzheimer's disease: Aβ, tau and synaptic dysfunction;F. LaFerla;Trends Mol. Med,2005
5. Tau protein pathology in Alzheimer's disease and related disorders;M. Tolnay;Neuropathol. Appl. Neurobiol,1999
Cited by
160 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献